

Curriculum Vitae



Akinori Sato, M.D., Ph.D.

Dr. Akinori Sato is the world's leading researcher investigating the feasibility of using drug repositioning, endoplasmic reticulum stress, and histone acetylation to treat urological malignancies. His other important interests involve German, Germany, J. Brahms, and J.S. Bach. His German knowledge is facilitating good communication and on-going international research projects with German universities. He is also an expert on medical education. His educational activity has been highly regarded (he received a Best Teacher Award in 2018) and his students' research projects have also received institutional and other awards.

Career

2015–present	Lecturer, National Defense Medical College
2006–2007	Visiting Researcher, Department of Urology, Heinrich Heine University, Düsseldorf, Germany
2006	Ph.D., Keio University
2004–present	Active Staff, Department of Urology, National Defense Medical College Hospital, Tokorozawa, Japan
2000	Certified Urologist of Japanese Urological Association.
1997–2001	Resident in Urology, Keio University and Its Affiliated Hospitals
1995–1997	Resident in Surgery, Keio University and Its Affiliated Hospitals
1995	M.D., Keio University, Tokyo, Japan

Education

1989–1995	School of Medicine, Keio University
1986–1989	Keio High School

Languages

Japanese, English, German

Areas of Expertise

Medical Education, Molecular Biology, Drug Repositioning, Endoplasmic Reticulum Stress, Histone Acetylation, Autophagy, Cancer Metabolism, Urology

Awards

2020	Suzuki Urology Foundation Research Grant (Dr. Kazuki Okubo)
2019	Medicine Innovates Key Scientific Article
2019	Publons the Top Peer Reviewer Award in Clinical Medicine
2019	Publons the Top Peer Reviewer Award in Cross-Field
2019	Foundation for Promotion of Defense Medicine Best Research Award
2018	Publons Peer Review Awards 2018 "Top 1% in Field"
2018	National Defense Medical College Best Teacher Award
2018	Institutional Basic Research Program Award (Medical Students)
2017	URO TODAY "Beyond the Abstract"
2017	The 32nd EAU Congress Best Poster Award
2017	The 26th Japanese Society for Molecular and Cellular Urology Annual Meeting Research Encouragement Award (Dr. Kazuki Okubo)
2017	Institutional Basic Research Program Award (Medical Students)
2014	The 102nd JUA Annual Meeting Award
2013	URO TODAY "Beyond the Abstract"
2013	Global Medical Discovery Key Scientific Article
2013	The 28th EAU Congress Best Poster Award
2012	The Journal of Urology "This Month in Investigative Urology"
2011	The 99th JUA Annual Meeting Award
2011	The 26th EAU Congress Best Poster Award
2011	The 76th Annual Meeting of the Eastern Section of JUA Poster Award
2010	National Defense Medical College Congress Award
2008	Tamura Award

Publications

1. Okubo K, Isono M, Miyai K, Asano T, Sato A: Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. *Cancer Sci.* 111, 112-126, 2020.
2. Okubo K, Isono M, Asano T, Sato A: Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells. *Anticancer Res.* 39, 5891-5901, 2019.
3. Okubo K, Isono M, Asano T, Sato A: Metformin augments panobinostat's anti-bladder cancer activity by activating AMP-activated protein kinase. *Transl Oncol.* 12, 669-682,

2019.

4. Isono M, Sato A, Asano T, Okubo K, Asano T: Evaluation of therapeutic potential of phenoxodiol, a novel isoflavone analog, in renal cancer cells. *Anticancer Res.* 38, 5709-5716, 2018.
5. Okubo K, Sato A, Nakamoto K, Hatanaka Y, Isono M, Hatanaka M, Suyama Y, Shinmoto H, Asano T: Bosniak category III renal cysts caused by crizotinib in an anaplastic lymphoma kinase gene-rearranged non-small cell lung cancer patient. *Urology.* 121, e3-e4, 2018.
6. Okubo K, Sato A, Isono M, Asano T, Asano T: Nelfinavir induces endoplasmic reticulum stress and sensitizes renal cancer cells to TRAIL. *Anticancer Res.* 38, 4505-4514, 2018.
7. Isono M, Sato A, Asano T, Okubo K, Asano T: Delanzomib interacts with ritonavir synergistically to cause endoplasmic reticulum stress in renal cancer cells. *Anticancer Res.* 38, 3493-3500, 2018.
8. Sato A, Asano T, Okubo K, Isono M, Asano T: Nelfinavir and ritonavir kill bladder cancer cells synergistically by inducing endoplasmic reticulum stress. *Oncol Res.* 26, 323-332, 2018.
9. Isono M, Sato A, Kimura F, Asano T: A case of mucosa-associated lymphoid tissue lymphoma of the bladder successfully treated with radiotherapy. *Urol Case Rep.* 16, 1-3, 2017.
10. Watanabe D, Horiguchi A, Tasaki S, Kuroda K, Sato A, Asakuma J, Ito K, Asano T, Shinmoto H: Clinical implication of ectopic liver lipid accumulation in renal cell carcinoma patients without visceral obesity. *Sci Rep.* 7, 12795, 2017.
11. Tachi K, Sato A, Kouzaki Y, Maeda T, Kawana A, Asano T: A case of bacillus Calmette-Guérin cystitis diagnosed with a novel loop-mediated isothermal amplification method. *Urol Case Rep.* 14, 24-26, 2017.
12. Ito K, Soga S, Seguchi K, Shinci Y, Masunaga A, Tasaki S, Kuroda K, Sato A, Asakuma J, Horiguchi A, Shinmoto H, Kaji T, Asano T. Clinical outcomes of percutaneous

- radiofrequency ablation for small renal cancer. *Oncol Lett.* 14, 918-924, 2017.
13. Sato A, Asano T, Okubo K, Isono M, Asano T: Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation. *Cancer Sci.* 108, 1194-1202, 2017.
 14. Sawazaki H, Ito K, Asano T, Kuroda K, Sato A, Asakuma J, Horiguchi A, Seguchi K, Asano T: Increased nucleophosmin expression is a strong predictor of recurrence and prognosis in patients with N0M0 upper tract urothelial carcinoma undergoing radical nephroureterectomy. *World J Urol.* 35, 1081-1088, 2017.
 15. Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J Jr, Niegisch G, Schulz WA: Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. *J Exp Clin Cancer Res.* 36, 1, 2017.
 16. Tasaki S, Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Asano T, Asakura H: Preoperative serum docosahexaenoic acid level predicts prognosis of renal cell carcinoma. *Mol Clin Oncol.* 5, 69-73, 2016.
 17. Isono M, Sato A, Asano T: A case of long-term survival of advanced paratesticular rhabdomyosarcoma treated with a multimodal therapy including a combination of cyclophosphamide, vincristine, doxorubicin and dacarbazine. *Urol Case Rep.* 7, 3-6, 2016.
 18. Ito K, Asakuma J, Kuroda K, Tachi K, Sato A, Horiguchi A, Seguchi K, Asano T: Preoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy. *Mol Clin Oncol.* 4, 530-536, 2016.
 19. Isono M, Sato A, Okubo K, Asano T, Asano T: Ritonavir interacts with belinostat to cause endoplasmic reticulum stress and histone acetylation in renal cancer cells. *Oncol Res.* 24, 327-335, 2016.
 20. Sato A: The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. *Onco Targets Ther.* 8, 761-768, 2015.
 21. Sato A, Isono M, Asano T, Okubo K, Ito K, Asano T: Ritonavir synergizes with carfilzomib to cause endoplasmic reticulum stress and autophagy in bladder cancer cells.

- Eur Med J. 3, 72, 2015.
22. Ito K, Seguchi K, Shimazaki H, Takahashi E, Tasaki S, Kuroda K, Sato A, Asakuma J, Horiguchi A, Asano T: Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma. *Oncol Lett.* 9, 125-130, 2015.
 23. Hamada S, Ito K, Kuroda K, Sato A, Asakuma J, Horiguchi A, Seguchi K, Asano T: Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. *Mol Clin Oncol.* 3, 63-68, 2015.
 24. Kouzaki Y, Maeda T, Sasaki H, Tamura S, Hamamoto T, Yuki A, Sato A, Miyahira Y, Kawana A: A simple and rapid identification method for mycobacterium bovis BCG with loop-mediated isothermal amplification. *PLoS One.* 10, e0133759, 2015.
 25. Kuroda K, Asakuma J, Asano T, Horiguchi A, Isono M, Tsujita Y, Sato A, Seguchi K, Ito K, Asano T: Clinical significance of p21-activated kinase 1 expression level in patients with upper urinary tract urothelial carcinoma. *Jpn J Clin Oncol.* 45, 103-110, 2015.
 26. Asano T, Sato A, Isono M, Okubo K, Ito K, Asano T: Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress. *Biomed Rep.* 3, 797-801, 2015.
 27. Ito K, Kuroda K, Asakuma J, Hamada S, Tachi K, Tasaki S, Sato A, Horiguchi A, Seguchi K, Asano T: Preoperative risk factors for extraurothelial recurrence in patients with ureteral cancer treated by radical nephroureterectomy. *J Urol.* 191, 1685-1692, 2014.
 28. Sato A, Asano T, Isono M, Ito K, Asano T: Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth. *Mol Clin Oncol.* 2, 1016-1022, 2014.
 29. Sato A, Isono M, Asano T, Okubo K, Ito K, Asano T: Ritonavir synergizes with carfilzomib to cause endoplasmic reticulum stress and autophagy in bladder cancer cells. *Eur Med J.* 3, 72, 2015.
 30. Ito K, Seguchi K, Yoshii H, Hamada S, Asakuma J, Tasaki S, Kuroda K, Sato A, Horiguchi A, Asano T: Modified posterior musculofascial plate reconstruction decreases

posterior vesicourethral angle and improves urinary continence recovery in patients undergoing laparoscopic radical prostatectomy. *Mol Clin Oncol.* 1, 970-976, 2015.

31. Sato A, Asano T, Isono M, Ito K, Asano T: Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. *BMC Urol.* 14, 71, 2014.
32. Sato A: Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. *Onco Targets Ther.* 5, 67-76, 2012.
33. Sato A, Asano T, Ito K, Asano T: Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. *J Urol.* 188, 2410-2418, 2012.
34. Kuroda K, Horiguchi A, Asano T, Tasaki S, Yoshii H, Sato A, Asakuma J, Ito K, Seguchi K, Sumitomo M, Asano T: Prediction of biochemical recurrence after radical prostatectomy using peritumoral lymphatic vessel density in biopsy specimens in patients with localized prostate cancer. *Urol Int.* 88, 18-24, 2012.
35. Sato A, Asano T, Ito K, Asano T: 17-allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1. *Int J Oncol.* 41, 46-52, 2012.
36. Sato A, Asano T, Ito K, Asano T: Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells. *Urology.* 79, 13-21, 2012.
37. Sato A, Asano T, Ito K, Sumitomo M, Asano T: Suberoylanilide hydroxamic acid in combination with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. *BJU Int.* 109, 1258-1268, 2012.
38. Kuroda K, Asakuma J, Horiguchi A, Tasaki S, Yoshii H, Sato A, Ito K, Seguchi K, Sumitomo M, Asano T: Prognostic factors for upper urinary tract urothelial carcinoma after nephroureterectomy. *Urol Int.* 88, 225-231, 2012.
39. Kuroda K, Horiguchi A, Asano T, Ito K, Asakuma J, Sato A, Yoshii H, Hayakawa M, Asano T: Glucose-regulated protein 78 positivity as a predictor of poor survival in

- patients with renal cell carcinoma. *Urol Int.* 87, 450-456, 2011.
40. Ito K, Yoshii H, Sato A, Kuroda K, Asakuma J, Horiguchi A, Sumitomo M, Asano T: Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. *J Urol.* 186, 430-435, 2011.
 41. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. *Oncol Res.* 19, 217-223, 2011.
 42. Sumitomo M, Asakuma J, Sato A, Ito K, Nagakura K, Asano T: Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer. *Int J Urol.* 17, 924-930, 2010.
 43. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Hayakawa M, Sumitomo M, Asano T: STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. *Br J Cancer.* 102, 1592-1599, 2010.
 44. Tobe M, Ito K, Umeda S, Sato A, Adaniya N, Tanaka Y, Hayakawa M, Asano T: Severe polyuria after the resection of adrenal pheochromocytoma. *Int J Urol.* 17, 1004-1007, 2010.
 45. Sumitomo M, Asakuma J, Yoshii H, Sato A, Horiguchi A, Ito K, Nagakura K, Asano T: Anterior perirectal fat tissue thickness is a strong predictor of recurrence after high-intensity focused ultrasound for prostate cancer. *Int J Urol.* 17, 776-782, 2010.
 46. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. *Urology.* 76, 764.e7-13, 2010.
 47. Ito K, Yoshii H, Asakuma J, Sato A, Horiguchi A, Sumitomo M, Hayakawa M, Asano T: Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens. *Jpn J Clin Oncol.* 39, 588-594, 2009.
 48. Sato A, Asano T, Ito K, Sumitomo M, Asano T, Hayakawa M: A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin

- expression by topotecan and hexamethylene bisacetamide. *Mol Med Rep.* 2, 423-428, 2009.
49. Sato A, Ito K, Asano T, Sumitomo M, Asano T, Hayakawa M: Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan. *Int J Oncol.* 32, 171-176, 2008.
 50. Sato A, Matsumoto K, Nakamura S: Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies? Authors' reply. *Int J Urol.* 14, 178, 2007.
 51. Sato A, Ito K, Asano T, Sumitomo M, Asano T, Hayakawa M: Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: Topotecan enhances liposome-mediated transfection by increasing cellular uptake. *Int J Oncol.* 30, 695-700, 2007.
 52. Ito K, Asano T, Yoshii H, Sato A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. *Int J Urol.* 13, 1365-1370, 2006.
 53. Sato A, Ohigashi T, Oya M, Nakashima J, Marumo K, Murai M: Clinicopathological features predicting nodal metastasis of testicular seminoma: Results from 100 cases in a single institute. *Urol Int.* 77, 64-68, 2006.
 54. Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Umezawa K, Hayakawa M, Murai M: Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. *Int J Oncol.* 28, 841-846, 2006.
 55. Sato A, Matsumoto K, Nakamura S: Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies? *Int J Urol.* 13, 224-227, 2006.
 56. Sato A, Hanawa Y, Nakamura S: Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical Bacille Calmette-Guerin therapy. *Int J Urol.* 11, 476-482, 2004.

57. Satoh A, Iigaya T: Multiple endocrine neoplasia type 1 with pyonephrosis. *Int J Urol.* 9, 402-404, 2002.
58. Satoh A, Mizuno R, Ikeuchi K: Spontaneous peripelvic extravasation secondary to ovarian cyst: A case report. *Acta Urol Jpn.* 47, 735-737, 2001.

Presentations at International Conferences

1. Sato A, Asano T, Okubo K: Vorinostat and ixazomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress. The 35th European Association of Urology Congress, Amsterdam, 2020. (Virtual)
2. Sato A, Asano T, Okubo K: Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in bladder cancer cells. The 35th European Association of Urology Congress, Amsterdam, 2020. (Virtual)
3. Okubo K, Asano T, Sato A: Simvastatin augments anticancer activity of romidepsin in bladder cancer cells by causing AMP-activated protein kinase activation and histone acetylation. The 35th European Association of Urology Congress, Amsterdam, 2020. (Virtual)
4. Asano T, Okubo K, Sato A: Ritonavir and oprozomib inhibit renal cancer growth by inducing endoplasmic reticulum stress. The 115th American Urological Association Annual Meeting, Washington, 2020. (Virtual)
5. Sato A: Die verschwundene Proteine: where are they? 12th Triennial Meeting German-Japanese Confederation of Urology, Akita, 2019.
6. Okubo K, Isono M, Asano T, Sato A: Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells by activating AMP activated protein kinase. The 114th American Urological Association Annual Meeting, Chicago, 2019.
7. Sato A, Asano T, Isono M, Okubo K: Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells. The 114th American Urological Association Annual Meeting, Chicago, 2019.

8. Sato A, Asano T, Isono M, Okubo K: Panobinostat and ritonavir cause bladder cancer apoptosis by inducing endoplasmic reticulum stress and histone acetylation synergistically. The 114th American Urological Association Annual Meeting, Chicago, 2019.
9. Asano T, Sato A, Isono M, Okubo K: Cobicistat, a potent inhibitor of CYP3A, enhances the antineoplastic activity of ixazomib in renal cancer cells. The 114th American Urological Association Annual Meeting, Chicago, 2019.
10. Isono M, Okubo K, Asano T, Sato A: The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in cisplatin-resistant bladder cancer cells. The 34th European Association of Urology Congress, Barcelona, 2019.
11. Sato A, Asano T, Isono M, Okubo K: Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells. The 34th European Association of Urology Congress, Barcelona, 2019.
12. Asano T, Sato A, Okubo K, Isono M, Asano T: Ritonavir and ixazomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically. The 113th American Urological Association Annual Meeting, San Francisco, 2018.
13. Sato A: Poster Session 79 Session Chair: Urothelial tumours: Molecular subtypes and clinical relevance. The 33rd European Association of Urology Congress, Copenhagen, 2018.
14. Sato A, Asano T, Okubo K, Isono M, Asano T: Ritonavir and oprozomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress. The 33rd European Association of Urology Congress, Copenhagen, 2018.
15. Okubo K, Sato A, Asano T, Isono M, Asano T: Metformin augments panobinostat's antineoplastic activity in bladder cancer cells by activating AMP-activated protein kinase. The 33rd European Association of Urology Congress, Copenhagen, 2018.
16. Isono M, Sato A, Okubo K, Asano T, Asano T: The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 sensitizes bladder cancer cells to gemcitabine. The 33rd

European Association of Urology Congress, Copenhagen, 2018.

17. Kawai Y, Zhang F, Akamatsu S, Hayashi T, Imada K, Beraldi E, Seiler R, Leong J, Oo H, Moskalev I, Fazli L, Sato A, Matsuyama H, Black P, Collins C, Gleave M: Inhibition of PEG10 may be a novel treatment strategy for a subset of bladder cancer. The 112th American Urological Association Annual Meeting, Boston, 2017.
18. Isono M, Sato A, Asano T, Okubo K, Asano T: Phenoxodiol, a novel soy isoflavone analog, inhibits Akt pathway and induces renal cancer apoptosis. The 112th American Urological Association Annual Meeting, Boston, 2017.
19. Okubo K, Sato A, Asano T, Isono M, Asano T: Nelfinavir acts synergistically with panobinostat to induce endoplasmic reticulum stress and inhibit renal cancer growth. The 112th American Urological Association Annual Meeting, Boston, 2017.
20. Okubo K, Sato A, Asano T, Isono M, Asano T: Lopinavir synergizes with ritonavir to cause renal cancer apoptosis via inducing endoplasmic reticulum stress. The 112th American Urological Association Annual Meeting, Boston, 2017.
21. Asano T, Sato A, Okubo K, Isono M, Asano T: Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of entinostat in renal cancer cells in vitro and in vivo. The 112th American Urological Association Annual Meeting, Boston, 2017.
22. Isono M, Sato A, Okubo K, Asano T, Hoffmann MJ, Schulz WA, Asano T: The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine. The 32nd European Association of Urology Congress, London, 2017.
23. Okubo K, Sato A, Asano T, Isono M, Asano T: Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress. The 32nd European Association of Urology Congress, London, 2017.
24. Sato A, Isono M, Asano T, Okubo K, Asano T: Panobinostat and ixazomib inhibit bladder cancer growth synergistically by increasing histone acetylation and inducing endoplasmic reticulum stress. The 32nd European Association of Urology Congress, London, 2017.
25. Sato A, Asano T, Okubo K, Isono M, Asano T: Ritonavir, a potent inhibitor of

P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells. The 32nd European Association of Urology Congress, London, 2017.

26. Sato A, Okubo K, Asano T, Isono M, Asano T: Lopinavir synergizes with ritonavir to induce bladder cancer apoptosis by causing histone acetylation and endoplasmic reticulum stress. The 32nd European Association of Urology Congress, London, 2017.
27. Sato A: Poster Session 73 Session Chair: Immune therapy and targeted therapy in urothelial cancer. The 32nd European Association of Urology Congress, London, 2017.
28. Sato A, Asano T, Isono M, Okubo K, Asano T: Ritonavir interacts with ixazomib synergistically to cause ubiquitinated protein accumulation and endoplasmic reticulum stress in bladder cancer cells. 24th Biennial Congress of the European Association for Cancer Research, Manchester, 2016.
29. Sato A: ER stress: A novel approach to treating urological malignancies. 11th Triennial Meeting German-Japanese Confederation of Urology, Hamburg, 2016.
30. Watanabe D, Horiguchi A, Tasaki S, Kuroda K, Sato A, Asakuma J, Ito K, Asano T, Shinmoto H: Ectopic lipid accumulation in liver is associated with tumor aggressiveness and poor prognosis in renal cell carcinoma. The 111th American Urological Association Annual Meeting, San Diego, 2016.
31. Isono M, Sato A, Okubo K, Asano T, Ito K, Asano T: Ritonavir synergizes with delanzomib to cause endoplasmic reticulum stress in renal cancer cells. The 111th American Urological Association Annual Meeting, San Diego, 2016.
32. Okubo K, Sato A, Asano T, Isono M, Ito K, Asano T: Nelfinavir induces endoplasmic reticulum stress and sensitizes renal cancer cells to tumor necrosis factor-related apoptosis-inducing ligand. The 111th American Urological Association Annual Meeting, San Diego, 2016.
33. Isono M, Sato A, Asano T, Okubo K, Schulz WA, Asano T: Ritonavir and delanzomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically. The 31st European Association of Urology Congress, Munich, 2016.

34. Sato A, Asano T, Isono M, Okubo K, Asano T: Combination of human immunodeficiency virus protease inhibitors causes bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress and histone acetylation. The 31st European Association of Urology Congress, Munich, 2016.
35. Isono M, Sato A, Asano T, Okubo K, Schulz WA, Asano T: Ritonavir synergizes with delanzomib to cause endoplasmic reticulum stress and autophagy in renal cancer cells. The 67th German Urological Association Annual Meeting, Hamburg, 2015.
36. Sawazaki H, Ito K, Asano T, Kuroda K, Sato A, Asakuma J, Horiguchi A, Seguchi K, Asano T: Prognostic impact of nucleophosmin/B23 expression in upper tract urothelial carcinoma (UTUC) in patients undergoing radical nephroureterectomy (RNU). The 110th American Urological Association Annual Meeting, New Orleans, 2015.
37. Sato A, Isono M, Asano T, Okubo K, Ito K, Asano T: Ritonavir synergizes with carfilzomib to cause endoplasmic reticulum stress and autophagy in bladder cancer cells. The 30th European Association of Urology Congress, Madrid, 2015.
38. Isono M, Sato A, Tsujita Y, Kuroda K, Asakuma J, Horiguchi A, Seguchi K, Ito K, Asano T: Is estimated glomerular filtration rate a significant predictor of prostate cancer? The 34th Congress of the Société Internationale d'Urologie, Glasgow, 2014.
39. Sato A: Clinical perspective in genitourinary malignancies. IAEA/RCA Regional Training Course, Inage, 2014.
40. Sato A: ER stress: A novel approach to treating urological malignancies. Urologische Klinik CE Meeting (Heinrich Heine University), Düsseldorf, 2014.
41. Isono M, Sato A, Asano T, Ito K, Asano T: Ritonavir interacts with belinostat to cause endoplasmic reticulum stress and histone acetylation synergistically in renal cancer cells. The 23rd Biennial Congress of the European Association for Cancer Research, Munich, 2014.
42. Sato A, Asano T, Isono M, Ito K, Asano T: Ubiquitinated protein accumulation: A novel approach to treating bladder cancer. The 23rd Biennial Congress of the European

Association for Cancer Research, Munich, 2014.

43. Kuroda K, Asakuma J, Asano T, Horiguchi A, Isono M, Tsujita Y, Sato A, Seguchi K, Ito K, Asano T: Impact of increased expression of both ras-related C3 botulinum toxin substrate 1 and p21-activated kinase 1 in patients with NOM0 upper urinary tract urothelial carcinoma. The 109th American Urological Association Annual Meeting, Orlando, 2014.
44. Asano T, Sato A, Isono M, Ito K, Asano T: Bortezomib interacts with belinostat to cause ubiquitinated protein accumulation synergistically in renal cancer cells. The 109th American Urological Association Annual Meeting, Orlando, 2014.
45. Sato A, Asano T, Isono M, Ito K, Asano T: Ritonavir synergizes with carfilzomib to induce endoplasmic reticulum stress and autophagy in renal cancer cells. The 109th American Urological Association Annual Meeting, Orlando, 2014.
46. Sato A, Asano T, Isono M, Ito K, Asano T: Romidepsin combined with ritonavir exhibits strong cytotoxicity in renal cancer cells by synergistically inducing histone acetylation and endoplasmic reticulum stress. The 109th American Urological Association Annual Meeting, Orlando, 2014.
47. Kimura T, Sato A, Kawaguchi M, Isono M, Tsujita Y, Kuroda K, Asakuma J, Horiguchi A, Seguchi K, Ito K, Asano T: Is lower Gleason score an independent predictor of biochemical relapse in prostate cancer patients treated with external-beam radiotherapy? The 4th Congress of Asia Pacific Prostate Society, Okinawa, 2014.
48. Sato A, Asano T, Isono M, Ito K, Asano T: A novel combination therapy using vorinostat and bortezomib to treat prostate cancer. The 4th Congress of Asia Pacific Prostate Society, Okinawa, 2014.
49. Kuroda K, Asakuma J, Horiguchi A, Tasaki S, Sato A, Seguchi K, Ito K, Asano T: Detection of factors affecting early bladder recurrence after nephroureterectomy in patients with NOM0 upper urinary tract urothelial carcinoma. The 108th American Urological Association Annual Meeting, San Diego, 2013.

50. Ito K, Kuroda K, Asakuma J, Hamada S, Tachi K, Tasaki S, Sato A, Horiguchi A, Seguchi K, Asano T: Preoperative risk factors for extravesical recurrence in patients with ureteral cancer who underwent radical nephroureterectomy. The 108th American Urological Association Annual Meeting, San Diego, 2013.
51. Sato A, Asano T, Ito K, Asano T: Ritonavir interacts with panobinostat to enhance histone acetylation and inhibit renal cancer growth synergistically. The 108th American Urological Association Annual Meeting, San Diego, 2013.
52. Sato A, Asano T, Ito K, Asano T: Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. The 108th American Urological Association Annual Meeting, San Diego, 2013.
53. Sato A, Asano T, Ito K, Asano T: Ritonavir combined with bortezomib synergistically induces endoplasmic reticulum stress and ubiquitinated protein accumulation in bladder cancer cells. The 108th American Urological Association Annual Meeting, San Diego, 2013.
54. Kuroda K, Asakuma J, Horiguchi A, Tasaki S, Sato A, Seguchi K, Ito K, Asano T: Detection of factors affecting early bladder recurrence after nephroureterectomy in patients with NOM0 upper urinary tract urothelial carcinoma. The 28th European Association of Urology Congress, Milan, 2013.
55. Sato A: Might cancer cells be killed by something accumulating in them? : The idea of treating urological malignancies by causing the accumulation of ubiquitinated proteins. Düsseldorf School of Oncology Kolloquien (Heinrich Heine University), Düsseldorf, 2013.
56. Sato A, Asano T, Ito K, Asano T: Bortezomib synergizes with vorinostat to cause ubiquitinated protein accumulation and histone acetylation in bladder cancer cells. The 28th European Association of Urology Congress, Milan, 2013.
57. Sato A, Asano T, Ito K, Asano T: Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in renal cancer cells in vitro and in vivo. The 28th

European Association of Urology Congress, Milan, 2013.

58. Sato A, Asano T, Ito K, Asano T: Ritonavir and bortezomib inhibit bladder cancer growth by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically. The 28th European Association of Urology Congress, Milan, 2013.
59. Sato A, Asano T, Ito K, Asano T: Panobinostat and bortezomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically. The 28th European Association of Urology Congress, Milan, 2013.
60. Kuroda K, Horiguchi A, Asano T, Tasaki S, Sato A, Asakuma J, Ito K, Seguchi K, Hayakawa M, Asano T: Prediction of biochemical recurrence after radical prostatectomy using a peritumoral lymphatic vessel density parameter in biopsy specimens from patients with localized prostate cancer. The 107th American Urological Association Annual Meeting, Atlanta, 2012.
61. Tasaki S, Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Seguchi K, Hayakawa M, Ito K, Asano T: Low levels of serum omega-3 polyunsaturated fatty acid are associated with tumor aggressiveness and poor prognosis in renal cell carcinoma. The 107th American Urological Association Annual Meeting, Atlanta, 2012.
62. Tasaki S, Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Seguchi K, Hayakawa M, Ito K, Asano T: Docosahexaenoic acid as a novel therapeutic agent for renal cell carcinoma. The 107th American Urological Association Annual Meeting, Atlanta, 2012.
63. Sato A, Asano T, Ito K, Asano T: Ritonavir interacts with bortezomib synergistically to enhance endoplasmic reticulum stress in prostate cancer cells. The 107th American Urological Association Annual Meeting, Atlanta, 2012.
64. Sato A: What wandering along the Rhein brought me: The idea of treating urological malignancies by causing the accumulation of ubiquitinated proteins. The 100th Japanese Urological Association Annual Meeting, Yokohama, 2012.
65. Sato A, Asano T, Ito K, Asano T: Vorinostat interacts with bortezomib to enhance protein

ubiquitination synergistically in prostate cancer cells. The 27th European Association of Urology Congress, Paris, 2012.

66. Hamada S, Ito K, Takahashi M, Isono M, Yoshii H, Tasaki S, Kuroda K, Sato A, Asakuma J, Seguchi K, Horiguchi A, Sumitomo M, Asano T: Clinical experience of laparoscopic nephroureterectomy in National Defense Medical College. 8th Annual Meeting of the East Asian Society of Endourology, Kyoto, 2011.
67. Hamada S, Ito K, Takahashi M, Isono M, Yoshii H, Tasaki S, Kuroda K, Sato A, Asakuma J, Seguchi K, Horiguchi A, Sumitomo M, Asano T: Clinical experience of laparoscopic nephroureterectomy in National Defense Medical College. 29th World Congress of Endourology and SWL, Kyoto, 2011.
68. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Hayakawa M, Sumitomo M, Asano T: Inhibition of the growth and tumor angiogenesis of renal cell carcinoma by a STAT3 inhibitor WP1066. The 106th American Urological Association Annual Meeting, Washington, 2011.
69. Kuroda K, Horiguchi A, Asano T, Tasaki S, Asakuma J, Yoshii H, Sato A, Ito K, Seguchi K, Sumitomo M, Asano T: Impact of increased expression of glucose-regulated protein 78 on clinicopathological parameters and prognosis in renal cell carcinoma. The 106th American Urological Association Annual Meeting, Washington, 2011.
70. Asakuma J, Sumitomo M, Horiguchi A, Asano T, Yoshii H, Tasaki S, Kuroda K, Sato A, Ito K, Seguchi K, Hayakawa M, Asano T: Heat shock protein 27 overexpression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. The 106th American Urological Association Annual Meeting, Washington, 2011.
71. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Ritonavir and bortezomib inhibit renal cancer growth by inducing endoplasmic reticulum stress and protein ubiquitination. The 106th American Urological Association Annual Meeting, Washington, 2011.
72. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Combination therapy with

- suberoylanilide hydroxamic acid and bortezomib induces histone acetylation and protein ubiquitination synergistically in renal cancer cells. The 106th American Urological Association Annual Meeting, Washington, 2011.
73. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Ritonavir and bortezomib inhibit renal cancer growth by enhancing protein ubiquitination synergistically. The 26th European Association of Urology Congress, Vienna, 2011.
74. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Renal cancer histone acetylation and protein ubiquitination enhanced synergistically by bortezomib and suberoylanilide hydroxamic acid. The 21st Meeting of the European Association for Cancer Research, Oslo, 2010.
75. Sato A, Asano T, Asakuma J, Horiguchi A, Ito K, Sumitomo M, Asano T: HIV protease inhibitor ritonavir increases heat sensitivity of renal cancer cells by inhibiting heat-induced NF-kappaB activation. The 21st Meeting of the European Association for Cancer Research, Oslo, 2010.
76. Ito K, Yoshii H, Kuroda K, Sato A, Asakuma J, Horiguchi A, Sumitomo M, Asano T: Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 renal cell carcinoma (RCC). The 105th American Urological Association Annual Meeting, San Francisco, 2010.
77. Horiguchi A, Asano T, Sato A, Asakuma J, Ito K, Sumitomo M, Hayakawa M, Asano T: Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. The 105th American Urological Association Annual Meeting, San Francisco, 2010.
78. Kuroda K, Horiguchi A, Asano T, Sumitomo M, Ito K, Asakuma J, Sato A, Hayakawa M, Asano T: Peritumoral lymphatic vessel density in prostate biopsy cores as predictor of lymphatic invasion in surgical specimens from radical prostatectomy. The 105th American Urological Association Annual Meeting, San Francisco, 2010.
79. Sato A, Asano T, Asakuma J, Horiguchi A, Ito K, Sumitomo M, Asano T: Combination

therapy with 17-allylamino-17-demethoxygeldanamycin and ritonavir inhibits expression of heat shock factor 1 in renal cancer cells. The 105th American Urological Association Annual Meeting, San Francisco, 2010.

80. Kawai T, Hiroi S, Sato A, Asano T, Naoi M, Aida S, Inada H, Miyajima K, Ishii Y, Kawashima K, Urata K, Hebisawa A: Respiratory and body fluid cytopathology ? Case presentations. The 17th Thai-Japanese Workshop in Diagnostic Cytopathology, Chiang Mai, 2010.
81. Sato A, Asano T, Asakuma J, Horiguchi A, Ito K, Sumitomo M, Asano T, Hayakawa M: Combination of 17-allylamino-17-demethoxygeldanamycin and ritonavir is effective against renal cancer cells. The 61th German Urological Association Annual Meeting, Dresden, 2009.
82. Sumitomo M, Asakuma J, Yoshii H, Horiguchi A, Sato A, Ito K, Hayakawa M, Asano T: Obesity as a strong predictor of biochemical recurrence after high-intensity focused ultrasound for prostate cancer. The 104th American Urological Association Annual Meeting, Chicago, 2009.
83. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Combined effects of suberoylanilide hydroxamic acid and ritonavir in renal cancer cells. The 104th American Urological Association Annual Meeting, Chicago, 2009.
84. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: A novel combination therapy using suberoylanilide hydroxamic acid and ritonavir to treat prostate cancer. The 104th American Urological Association Annual Meeting, Chicago, 2009.
85. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T: Combined effects of suberoylanilide hydroxamic acid and ritonavir in renal cancer cells. The 13th World Congress on Advances in Oncology, Crete, 2008.
86. Ito K, Asano T, Asano T, Sato A, Sumitomo M, Hayakawa M: Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma. The 102nd American

Urological Association Annual Meeting, Anaheim, 2007.

87. Satoh A, Nakamura S: Interval between biopsies is a significant predictor of prostate cancer at repeat biopsies. The 27th Congress of the Société Internationale d'Urologie, Honolulu, 2004.
88. Satoh A, Oya M, Mizuno R, Horiguchi Y, Ohigashi T, Nakashima J, Marumo K, Umezawa K, Murai M: Correlation between survivin expression and cell proliferation in renal cell carcinoma: regulation of survivin by insulin-like growth factor-1, interferon- γ and a novel NF- κ B inhibitor dehydroxymethyl-epoxyquinomicin. The 99th American Urological Association Annual Meeting, San Francisco, 2004.
89. Satoh A, Hanawa Y, Ohigashi T, Nakashima J, Marumo K, Murai M: Characteristics of testicular seminoma: A clinical study. The 26th Congress of the Société Internationale d'Urologie, Stockholm, 2002.

More Information

https://www.researchgate.net/profile/Akinori_Sato6

<https://scholar.google.com/citations?user=JFxEMYcAAAAJ&hl=ja>

Contact

zenpaku@ndmc.ac.jp